Stuart Poulton, EVP, Chief Development Officer at Karyopharm Therapeutics Inc. (KPTI), sold 22,466 shares at $1.20 ($26K) on 2024-03-01, disclosed to the SEC on 2024-03-04.
Open-market sale of $26k KPTI by EVP, Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.17 | 16,311 | $19K | 72.1% |
| 2 | $1.20 | 6,155 | $7K | 27.9% |
| Total | $1.18 avg | 22,466 | $26K | 100% |
| Filing → |
| KPTI | SELL | 2026-03-03 | $48K | — | Filing → |
| KPTI | SELL | 2026-02-19 | $3K | — | Filing → |
| KPTI | SELL | 2025-09-16 | $3K | — | Filing → |